Literature DB >> 28149908

Acquired resistance mechanisms to immunotherapy.

Teresa Amaral1, Claus Garbe2.   

Abstract

Year:  2016        PMID: 28149908      PMCID: PMC5233497          DOI: 10.21037/atm.2016.12.21

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  18 in total

1.  Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Authors:  Willy Hugo; Hubing Shi; Lu Sun; Marco Piva; Chunying Song; Xiangju Kong; Gatien Moriceau; Aayoung Hong; Kimberly B Dahlman; Douglas B Johnson; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2015-09-10       Impact factor: 41.582

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

5.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Authors:  Antoni Ribas; Omid Hamid; Adil Daud; F Stephen Hodi; Jedd D Wolchok; Richard Kefford; Anthony M Joshua; Amita Patnaik; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Peter Hersey; Roxana Dronca; Richard W Joseph; Hassane Zarour; Bartosz Chmielowski; Donald P Lawrence; Alain Algazi; Naiyer A Rizvi; Brianna Hoffner; Christine Mateus; Kevin Gergich; Jill A Lindia; Maxine Giannotti; Xiaoyun Nicole Li; Scot Ebbinghaus; S Peter Kang; Caroline Robert
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

Review 6.  Cancer drug resistance: an evolving paradigm.

Authors:  Caitriona Holohan; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 7.  Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.

Authors:  Francesco Spagnolo; Paola Ghiorzo; Paola Queirolo
Journal:  Oncotarget       Date:  2014-11-15

8.  Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

Authors:  Ilaria Penna; Alessandra Molla; Giulia Grazia; Loredana Cleris; Gabriella Nicolini; Federica Perrone; Benedetta Picciani; Michele Del Vecchio; Filippo de Braud; Roberta Mortarini; Andrea Anichini
Journal:  Oncotarget       Date:  2016-01-26

9.  Suppression of B-Raf(V600E) cancers by MAPK hyper-activation.

Authors:  Rawan Atiq; Rachel Hertz; Sophia Eldad; Elia Smeir; Jacob Bar-Tana
Journal:  Oncotarget       Date:  2016-04-05

10.  Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Authors:  Michael P Smith; Holly Brunton; Emily J Rowling; Jennifer Ferguson; Imanol Arozarena; Zsofia Miskolczi; Jessica L Lee; Maria R Girotti; Richard Marais; Mitchell P Levesque; Reinhard Dummer; Dennie T Frederick; Keith T Flaherty; Zachary A Cooper; Jennifer A Wargo; Claudia Wellbrock
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 38.585

View more
  1 in total

Review 1.  Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?

Authors:  Sultana Mehbuba Hossain; Chiemi F Lynch-Sutherland; Aniruddha Chatterjee; Erin C Macaulay; Michael R Eccles
Journal:  Epigenomes       Date:  2021-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.